European Lung Cancer Working Party

Quick facts

Phase 3 pipeline

• Cisplatin + etoposide · Oncology
  Cisplatin and etoposide work together as a chemotherapy combination: cisplatin cross-links DNA to prevent replication, while etoposide inhibits topoisomerase II to block DNA unwinding and repair.
• Cisplatin, Ifosfamide, Gemcitabine · Oncology
  This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
• Epirubicin + ifosfamide + etoposide · Oncology
  This combination chemotherapy regimen uses three cytotoxic agents that damage DNA and disrupt cell division to kill rapidly dividing cancer cells.
• Ifosfamide, Gemcitabine · Oncology
  This combination of ifosfamide and gemcitabine uses two chemotherapy agents that damage DNA and inhibit nucleotide synthesis to kill rapidly dividing cancer cells.

Phase 2 pipeline

• Adriamycin, cyclophosphamide, vindesine, valproic acid · Oncology
  Adriamycin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II, and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Vindesine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and cell division. Valproic acid is a histone deacetylase inhibitor that modulates gene expression.
• Valproate plus doxorubicin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• European Lung Cancer Working Party portfolio CI brief
• European Lung Cancer Working Party pipeline updates RSS